Biospecimen Core Resource Facility

Known as: BCR, Biospecimen Core Resource 
A central facility to qualify, quality assure, and distribute human biomolecules in support of the development of the Cancer Genome Atlas (TCGA… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2005
Highly Cited
2005
Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Antiapoptotic members of the bcl-2 family have recently been implicated in the pathogenesis of chronic myeloid leukemia (CML), a… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2004
Review
2004
Regulation of the c-Abl and Bcr–Abl tyrosine kinases
The prototypic non-receptor tyrosine kinase c-Abl is implicated in various cellular processes. Its oncogenic counterpart, the Bcr… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer.
We previously showed that type I interferon-induced, Cre-mediated ablation of surface BCR expression in mature B cells through Ig… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Through sequencing analysis of blood or bone marrow samples from patients with chronic myeloid leukemia, we identified BCR-ABL… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2002
Highly Cited
2002
BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.
Clinical resistance to imatinib mesylate is commonly observed in patients with advanced Philadelphia chromosome- positive (Ph… (More)
  • figure 1
  • table 1
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Reversibility of acute B-cell leukaemia induced by BCR–ABL1
Cancer is thought to arise from multiple genetic events that establish irreversible malignancy. A different mechanism might be… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Signal Transducer and Activator of  Transcription (STAT)5 Activation by BCR/ABL Is Dependent on Intact Src Homology (SH)3 and SH2 Domains of BCR/ABL and Is Required for Leukemogenesis
Signal transducer and activator of transcription (STAT)5 is constitutively activated in BCR/ ABL-expressing cells, but the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
1996
Highly Cited
1996
Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl
Bcr/Abl is a chimeric oncogene that can cause both acute and chronic human leukemias. Bcr/Abl-encoded proteins exhibit elevated… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
1994
Highly Cited
1994
BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death.
Apoptosis is the major form of cell death associated with the action of chemotherapeutic agents on tumor cells, and therefore the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
1990
Highly Cited
1990
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
Oncogenic activation of the proto-oncogene c-abl in human leukemias occurs as a result of the addition of exons from the gene bcr… (More)
Is this relevant?